DNA methylation as prognostic factors in non-muscle-invasive bladder cancer: a systematic review and meta-analysis
Open Access
- 25 November 2025
- journal article
- review article
- Published by Frontiers Media SA in Oncology Reviews
- Vol. 19, 1679974
Abstract
Introduction: Early prognostication in non-muscle-invasive bladder cancer (NMIBC) is essential for optimizing therapy and follow-up. Epigenetic mechanisms, particularly DNA methylation, have emerged as promising biomarkers for predicting disease outcome. Materials and Methods: A systematic review and meta-analysis were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to evaluate the prognostic significance of promoter DNA methylation in NMIBC. Comprehensive searches of PubMed, Web of Science, Embase, MEDLINE, and the Cochrane Library (January 2010–October 2022) identified eligible studies. The Newcastle–Ottawa scale was used for quality assessment, and pooled hazard ratios with 95% confidence intervals were calculated using random-effects models. Results: Eleven studies with 3,065 NMIBC patients were analyzed. Promoter methylation was significantly associated with poor progression-free survival (pooled hazard ratios (HR) = 2.88; 95% CI = 2.03–4.09; p < 0.0001) and recurrence-free survival (pooled HR = 2.65; 95% CI = 1.93–3.63; p < 0.0001). Although overall survival showed pathway-specific variation (pooled HR = 0.96; 95% CI = 0.36–2.60; p = 0.94), methylation of adhesion and apoptosis-related genes exhibited the strongest associations. Subgroup analyses revealed a greater prognostic impact in Asian cohorts (p < 0.0001), suggesting regional differences in epigenetic susceptibility. Conclusion: Promoter DNA methylation constitutes a robust prognostic biomarker for recurrence and progression in NMIBC, with stronger effects in Asian populations. Standardization of validated gene panels, assay thresholds, and cross-regional prospective validation will be essential for clinical translation. Integrating methylation-based classifiers into risk stratification models could improve individualized management and long-term outcomes in NMIBC.Keywords
This publication has 49 references indexed in Scilit:
- 285P Genetic variation of the inflammatory cytokine Interleukin 17 in non-muscle invasive bladder cancerAnnals of Oncology, 2024
- Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation studyWorld Journal of Urology, 2024
- FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapiesCancer Communications, 2024
- Metabolomic Biomarkers for Prognosis in Non-Muscle Invasive Bladder Cancer: A Comprehensive Systematic Review and Meta-AnalysisIndian Journal of Clinical Biochemistry, 2024
- Tumor cell metabolism and autophagy as therapeutic targets2022
- PRISMA2020 : An R package and Shiny app for producing PRISMA 2020‐compliant flow diagrams, with interactivity for optimised digital transparency and Open SynthesisCampbell Systematic Reviews, 2022
- Associated pathogenesis of bladder cancer and SARS-CoV-2 infection: a treatment strategyVirusDisease, 2021
- HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array‐based DNA methylation and expression profilingInternational Journal of Cancer, 2013
- Novel combination markers for predicting progression of nonmuscle invasive bladder cancerInternational Journal of Cancer, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010